Crispr Therapeutics AG (CRSP)

Crispr Therapeutics AG (CRSP) Financial Statements


Crispr Therapeutics AG Financial Overview

Crispr Therapeutics AG's market cap is currently ―. The company's EPS TTM is $-8.37; its P/E ratio is -5.19; Crispr Therapeutics AG is scheduled to report earnings on May 9, 2023, and the estimated EPS forecast is $-1.92. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue$ 6.00K$ 94.00K$ 158.00K$ 178.00K$ 12.90M
Gross Profit$ -6.82M$ -38.77M$ -33.76M$ -30.47M-
EBIT$ -131.54M$ -182.39M$ -183.26M$ -175.97M$ -145.70M
EBITDA$ -125.69M$ -177.37M$ -175.99M$ -169.93M$ -139.44M
Net Income Common Stockholders$ -110.58M$ -174.55M$ -185.83M$ -179.22M$ -141.25M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.82B$ 1.90B$ 2.07B$ 2.22B$ 2.38B
Total Assets$ 2.24B$ 2.35B$ 2.46B$ 2.61B$ 2.75B
Total Debt$ 244.02M$ 242.16M$ 242.43M$ 238.98M$ 225.03M
Net Debt$ -1.57B$ -1.65B$ -1.82B$ -1.98B$ -2.15B
Total Liabilities$ 367.58M$ 399.40M$ 372.53M$ 361.26M$ 352.42M
Stockholders Equity$ 1.88B$ 1.95B$ 2.09B$ 2.24B$ 2.40B
Cash Flow-
Free Cash Flow$ -119.52M$ -111.23M$ -151.59M$ -150.59M$ -95.22M
Operating Cash Flow$ -113.33M$ -105.22M$ -141.96M$ -135.24M$ -86.04M
Investing Cash Flow$ -175.53M$ 87.46M$ -56.07M$ -114.52M$ -8.72M
Financing Cash Flow$ 2.48M$ 15.11M$ 10.35M$ 10.65M$ 6.30M
Currency in USD

Crispr Therapeutics AG Earnings and Revenue History

Crispr Therapeutics AG Debt to Assets

Crispr Therapeutics AG Cash Flow

Crispr Therapeutics AG Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis